December 4, 2022

Moderna Inc. mRNA,
-0.31%
on Wednesday said it expects supply issues for its new COVID-19 booster to be resolved “in the coming days”.

– Advertisement –

many media outlets reported this week That the lack of Moderna’s updated booster was the result of an ongoing inspection by the US Food and Drug Administration of a plant in Bloomington, Ind., which is operated by Catalent Inc. CTLT,
-1.82%,
Moderna and Catalent entered into an agreement in 2020 to manufacture Moderna’s COVID-19 vaccines.

– Advertisement –

Inspection is complete, and the FDA on Tuesday allowed 10 delayed batches of the vaccine to be shipped, saying that “the agency has no concerns with the safety, effectiveness, or quality of these batches.”

“We continue to see high demand in certain areas of the country,” a Moderna spokesperson told MarketWatch in an email. “We expect these availability constraints to be resolved in the coming days.”

– Advertisement –

The company said it still plans to deliver 70 million doses of its bivalent COVID-19 booster by the end of the year. The updated booster — called the bivalent shot — protects against the original strain of the virus as well as the BA.4 and BA.5 subtypes of omicron.

The US government has so far shipped more than 25 million doses of the new shots, primarily the bivalent vaccine developed by BioNTech SE BNTX,
-1.33%
and Pfizer Inc. pfe,
-0.55%,
according to Reuters,

Other COVID-19 news to know:

See also  Amazon loses effort to exclude Jassy and Bezos from testifying in FTC Prime probe